GO
Loading...

Takeover Bids

More

  • GE's big bid for Alstom  Wednesday, 30 Apr 2014 | 10:47 AM ET

    Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.

  • GE CEO confident Alstrom deal will go through  Wednesday, 30 Apr 2014 | 9:36 AM ET

    Jeffrey Immelt, General Electric chairman & CEO, discusses how the synergies between GE and Alstrom will likely drive earnings and increase the company's industrial mix.

  • Alstom backs GE bid but Siemens sweetens deal  Wednesday, 30 Apr 2014 | 7:02 AM ET

    CNBC's Mary Thompson reports the latest details on General Electric's attempt to acquire French company Alstom.

  • Alstrom bidding war standoff: GE vs. SI  Wednesday, 30 Apr 2014 | 6:07 AM ET

    Nicholas Heymann, William Blair analyst, discusses General Electric's attempt to acquire Alstrom but Germany's Siemens AG is not giving up its pursuit either. Currently GE has the green light from Alstrom shareholders, says Heymann.

  • Siemens will make Alstom offer: Report  Tuesday, 29 Apr 2014 | 11:11 AM ET

    CNBC's David Faber reports Siemens will make an offer for Alstonm.

  • Pfizer engaging in legal tax avoidance: Bernstein  Monday, 28 Apr 2014 | 3:21 PM ET

    Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.

  • Pfizer, AstraZeneca about drug pipeline: Pro  Monday, 28 Apr 2014 | 11:23 AM ET

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.

  • Pfizer pushes for $100 billion AstraZeneca deal  Monday, 28 Apr 2014 | 10:10 AM ET

    Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.

  • AstraZeneca not a great company: Cramer  Monday, 28 Apr 2014 | 9:01 AM ET

    The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.

  • Hedge fund & big pharma pair up  Wednesday, 23 Apr 2014 | 1:32 PM ET

    CNBC's Dominic Chu provides a timeline of Bill Ackman's stake in Allergan.

  • Carl Icahn's take on Ackman & Valeant  Wednesday, 23 Apr 2014 | 9:19 AM ET

    Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.

  • Cramer: Can't lose if you're Ackman  Wednesday, 23 Apr 2014 | 9:17 AM ET

    The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.

  • Ackman: Partnership with Valeant is not front running  Wednesday, 23 Apr 2014 | 7:48 AM ET

    William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant  Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • Valeant CEO: Deal will get done despite 'poison pill'  Wednesday, 23 Apr 2014 | 7:37 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets  Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold  Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Einhorn's new course  Tuesday, 22 Apr 2014 | 2:31 PM ET

    Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.

  • Pharma deal frenzy  Tuesday, 22 Apr 2014 | 10:01 AM ET

    CNBC's Meg Tirrell digs into the friendly and hostile M&A action taking place in pharmaceuticals, including a deal between Novartis and GlaxoSmithKline, and Valeant Pharmaceuticals bid for Allergan.

  • Valeant's offer for Allergan  Tuesday, 22 Apr 2014 | 8:03 AM ET

    Valeant Pharmaceuticals offered $48.30 share cash, as well as 0.83 shares for Allergan. CNBC's Meg Tirrell provides insight.